HOLDINGS
CURE HOLDINGS
Drug Delivery
Cure Holdings is a diversified healthcare and life sciences platform focused on the development, manufacturing, licensing, and commercialization of advanced pharmaceutical, biotechnology, and healthcare technologies. The company is strategically structured across three primary operating divisions: Research & Development, Compound Pharmacy Operations, and Pharmaceutical Licensing & Commercialization. Through this integrated platform, Cure Holdings is building a scalable healthcare ecosystem designed to accelerate innovation, improve patient outcomes, and address some of the largest and fastest growing global healthcare markets.
At the core of the organization is a strong focus on next generation drug delivery technologies, precision therapeutics, and high value pharmaceutical commercialization opportunities. Cure Holdings combines scientific innovation, intellectual property development, regulatory strategy, manufacturing capabilities, and commercialization expertise to create differentiated healthcare solutions across multiple therapeutic categories including metabolic disease, obesity management, vaccines, sexual health, nutraceuticals, and specialty pharmaceuticals.
A major strategic asset within the Cure Holdings platform is CURE Pharmaceutical’s proprietary CUREfilm® oral thin film delivery technology, a patent protected platform designed to improve bioavailability, patient compliance, convenience, portability, and administration efficiency across a wide range of pharmaceutical and nutraceutical applications. The platform utilizes advanced oral thin film, encapsulation, microemulsion, and nano delivery technologies that allow active pharmaceutical ingredients to be delivered rapidly through buccal and sublingual absorption while bypassing first pass metabolism.
The company believes these technologies have the potential to transform delivery methods for numerous therapeutic categories traditionally dependent on injections, pills, refrigeration, or less efficient oral delivery systems. The platform is being positioned across multiple high growth sectors including diabetes, GLP-1 weight management therapies, vaccines, erectile dysfunction treatments, nutraceuticals, and companion animal health.
Cure Holdings is strategically focused on some of the largest and fastest growing pharmaceutical markets in the world. These include obesity and diabetes management, where global demand for GLP-1 therapies and metabolic treatments continues to accelerate rapidly, as well as large scale global vaccine markets, specialty pharmaceutical applications, and consumer wellness categories. The company’s technologies are designed to address critical industry challenges including poor patient adherence, injection avoidance, refrigeration logistics, rural healthcare accessibility, bioavailability limitations, and inefficient delivery systems.
Within metabolic health and obesity management, Cure Holdings is advancing oral thin film applications for GLP-1 related therapies including semaglutide formulations designed to improve convenience, accessibility, and patient experience. The company is targeting a global obesity and diabetes market that many analysts project to exceed well over $100 billion in the coming years.
In diabetes care, the company is developing innovative insulin delivery approaches utilizing oral thin film technologies intended to eliminate many of the challenges associated with traditional injectable insulin therapies, including needle anxiety, refrigeration requirements, transportation complexity, and patient compliance barriers. Cure Holdings believes these solutions could create meaningful opportunities in underserved global markets where cold chain logistics and healthcare access remain major limitations.
The company is also pursuing opportunities in vaccine delivery technologies through oral and mucosal administration approaches designed to improve patient compliance, simplify logistics, and potentially expand vaccine accessibility in both developed and emerging markets. Additional growth initiatives include pharmaceutical compound manufacturing, specialty formulations, nutraceutical products, and strategic pharmaceutical licensing initiatives designed to accelerate commercialization and revenue generation.
Cure Holdings’ operating strategy combines internally developed intellectual property, regulatory expertise, strategic partnerships, compound manufacturing capabilities, and licensing opportunities to create multiple pathways toward commercialization. The company maintains a substantial and expanding intellectual property portfolio consisting of issued patents, pending patents, proprietary formulations, and trade secrets intended to support long term competitive advantages across its healthcare platform.
The organization’s integrated structure allows it to participate across multiple segments of the pharmaceutical value chain including scientific research, formulation development, specialty manufacturing, regulatory pathways, licensing transactions, and commercial product expansion. This diversified approach positions Cure Holdings to pursue scalable opportunities in both prescription and consumer healthcare markets while maintaining flexibility across evolving healthcare trends and emerging therapeutic categories.
Driven by innovation, patient accessibility, and next generation healthcare delivery systems, Cure Holdings is building a comprehensive life sciences platform focused on addressing major global healthcare needs through advanced pharmaceutical technologies, strategic commercialization, and scalable healthcare solutions.
